VenatoRx Pharmaceuticals is a private pharmaceutical company dedicated to the discovery and development of novel agents to address the threat of antibiotic bacteria resistance. Its lead clinical program combines VNRX-5133, a novel β-lactamase inhibitor, with an approved and marketed β-lactam antibiotic.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/26/17 | $42,000,000 | Series B |
Abingworth Foresite Capital Versant Ventures  | undisclosed |
